The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Aurora A kinase inhibitor alisertib and chemo is promising for untreated high-risk AML
Amir Fathi, MD, MPH, of the Massachusetts General Hospital, Boston, MA, discusses the Phase II trial of the Aurora A kinase inhibitor alisertib, combined with induction chemotherapy, in untreated high-risk acute myeloid leukemia (AML) patients (NCT02560025). This revealed an efficacious regimen, with promising remission and survival rates. This data was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
